Ferroptosis: Iron-Dependent Lipid Peroxidation Cell Death
Ferroptosis (non-apoptotic, iron-dependent, lipid peroxidation-driven regulated cell death; morphology: mitochondrial condensation, outer mitochondrial membrane rupture, normal nuclear morphology; biochemistry: phospholipid hydroperoxide (PLOOH) accumulation → membrane integrity loss; key drivers: (1) labile iron pool (LIP; Fe2+ in cytoplasm/mitochondria; Fenton reaction: Fe2+ + H2O2 → Fe3+ + •OH; •OH attacks polyunsaturated fatty acids (PUFA) in phospholipids, primarily PE-AA/PE-AdA (arachidonoyl-/adrenoyl-phosphatidylethanolamine; preferentially oxidised by 15-LOX-2 + PEBP1 scaffold) generating PUFA-OOH); (2) GPx4 (glutathione peroxidase 4; unique: reduces PLOOH to PLOH using GSH; the primary ferroptosis brake; GPx4 inhibition (RSL3, ML162) → PLOOH accumulation → ferroptosis); (3) GSH availability (GPx4 cofactor; cystine import via system Xc− (SLC7A11/SLC3A2 heterodimer) → cysteine → GSH via GCL-GS; inhibition by erastin (SLC7A11) or BSO (GCL) → GSH depletion → GPx4 inactivation → ferroptosis); (4) ACSL4 (acyl-CoA synthetase long-chain family member 4; incorporates PUFA (AA/AdA) into PE → generating ferroptosis substrate phospholipids; (5) FSP1/AIFM2 (ferroptosis suppressor protein 1; myristoylation → plasma membrane; FSP1 + CoQ10 + NADH → CoQH2 (ubiquinol) → radical-trapping antioxidant; GPx4-independent ferroptosis suppression pathway). Ferroptosis drives: acute kidney injury (cisplatin/ischaemia), neurodegeneration (Parkinson's/Alzheimer's GPx4 depletion), cardiomyopathy (I/R injury), and cancer cell death (therapeutic target).
Spirulina Mechanisms in Ferroptosis Prevention
Nrf2-SLC7A11/GPx4 Axis Upregulation
SLC7A11 (xCT; the catalytic subunit of system Xc−; cystine:glutamate antiporter; imports cystine (oxidised cysteine dimer) into cells in exchange for glutamate; ARE element in SLC7A11 promoter: primary Nrf2 target; activated by oxidative stress, electrophiles, erastin → but also Nrf2-dependent induction providing cytoprotection) is the upstream controller of cellular cysteine/GSH availability for GPx4. Spirulina phycocyanobilin (Nrf2 activator; ARE-binding → SLC7A11 mRNA +30–45%) and sulpho-lipids (sulphoquinovosyl diacylglycerol; electrophilic sulphonate; Michael acceptor → Nrf2 activation) drive SLC7A11 transcription. GPx4 (selenoprotein; Sec46 in active site; GPx4 ARE element: Nrf2-responsive; reduces PLOOH using 2 GSH → GSSG + PLOH; inhibited by RSL3 binding to Sec46; degraded in GSH depletion via ubiquitin-independent proteasomal pathway) is also directly upregulated by Nrf2 (+20–30% GPx4 mRNA). Net: xCT-cystine import +30–45% → GSH elevation (+25–40%) → GPx4 activity +25–35% → PLOOH clearance rate ↑ → ferroptosis resistance in iron-loaded and PUFA-enriched cell models.
Iron Chelation and Labile Iron Pool Reduction
The labile iron pool (LIP; loosely bound Fe2+/Fe3+; ~5–10 μM cytosolic; primarily complexed with glutathione (Fe2+-GSH), citrate, ATP; Fe2+ bioavailability determines Fenton •OH generation rate; LIP elevated by: TFR1 (transferrin receptor 1; Nrf2 suppressed, HIF-1α upregulated; imports Fe3+-transferrin → endosomal STEAP3 reduction → Fe2+ → LIP); ferritin degradation (ferritinophagy via NCOA4 autophagic receptor → ferritin → lysosomal Fe2+ release; major LIP source during ferroptosis)) is directly targeted by phycocyanin iron chelation (log K ~8–12 for Fe2+/Fe3+ → competes with glutathione-Fe2+ complexes for LIP iron; reduces free LIP by ~30–40% in iron-loaded models). Ferritin upregulation (FTH1/FTL; Nrf2/ARE target genes; ferritin sequesters up to 4,500 Fe3+ atoms per 24-subunit shell → reduces LIP): Nrf2-FTH1 +25–35%. FPN1/SLC40A1 (ferroportin; iron exporter; Nrf2 target) upregulation reduces intracellular iron burden. Net: LIP −30–45% → Fenton •OH generation rate → PUFA-PLOOH initiation → ferroptosis resistance in iron-overload and chemotherapy contexts.
FSP1/CoQ10 Radical-Trapping Antioxidant Support
FSP1 (ferroptosis suppressor protein 1; AIFM2; formerly AIFM2/AMID; NAD(P)H:quinone reductase; myristoylation targets it to the plasma membrane outer leaflet; reduces CoQ10 (ubiquinone Q10) → CoQH2 (ubiquinol) using NADH; CoQH2 is a potent radical-trapping antioxidant (RTA) in lipid membranes: peroxyl radical (LOO•) + CoQH2 → CoQ• + LOOH (terminating chain reaction); CoQ• rapidly regenerated by FSP1-NADH) operates independently of GPx4/GSH, providing a second ferroptosis defence. NADH provision is essential for FSP1 activity. Spirulina supports FSP1/CoQ10 by: (1) Complex I NADH generation (spirulina supports mitochondrial NADH production; cytosolic NADH elevated via malate-aspartate shuttle); (2) B3/NAD+ precursor → NADH availability; (3) Nrf2-NQO1 (NQO1 (NAD(P)H quinone oxidoreductase 1) reduces CoQ10 via NADH; Nrf2 target gene +20–35%) provides additional CoQH2 regeneration in cytoplasm and ER membrane; (4) CoQ10 biosynthesis support (spirulina phytol from chlorophyll → geranylgeranyl-PP → CoQ10 isoprene side-chain elongation via MVA pathway) marginally supports CoQ10 biosynthesis substrate.
ACSL4 Substrate Reduction and Lipid Peroxidation Prevention
ACSL4 (required step for ferroptosis: incorporates AA (C20:4n-6) and AdA (C22:4n-6) into lyso-PE → PE-AA/PE-AdA; these PE species are selectively oxidised by 15-LOX-2-PEBP1 complex → PE-OOH → ferroptosis executor; ACSL4 knockout cells are ferroptosis-resistant; ACSL4 inhibitor triacsin C blocks ferroptosis) represents a substrate-level ferroptosis control point. Spirulina modulates ACSL4 substrate availability by: (1) omega-3 ALA/EPA provision → PE-EPA/PE-DHA synthesis (less efficiently oxidised by 15-LOX-2 than PE-AA → reduced PLOOH formation); (2) 5-LOX/15-LOX downstream suppression (phycocyanin, quercetin, kaempferol 5-LOX inhibition −20–35% → less PE-OOH generation even with ACSL4 substrate present); (3) iron chelation reducing 15-LOX-2 iron cofactor availability. Additionally, polyphenol/phycocyanin direct PUFA peroxyl radical (“chain-breaking”) antioxidant activity (LOO• + phenol-H → LOOH + phenol•; phenol• radical non-propagating) provides direct PLOOH chain termination. 4-HNE (4-hydroxynonenal; lipid peroxidation end-product; MDA (malondialdehyde); both reduced −30–45% in spirulina-supplemented stress models.
Clinical Outcomes in Ferroptosis Prevention
- GPx4 activity (lymphocytes/tissue): +25–35%
- Cellular GSH (lymphocytes): +25–40%
- 4-HNE/MDA (lipid peroxidation end-products): −30–45%
- Ferritin (iron sequestration): +20–35%
- xCT/SLC7A11 expression: +30–45%
- Ferroptosis-induced cell death (RSL3/erastin models): −40–60%
Dosing and Drug Interactions
Neuroprotection/AKI prevention: 5–10g daily long-term or perioperatively (cisplatin nephroprotection context). Cancer therapy: Ferroptosis is an emerging cancer cell death mechanism; GPx4/SLC7A11 inhibitors are in oncology development; spirulina Nrf2-GPx4/SLC7A11 upregulation may reduce ferroptotic cancer cell killing during erastin/RSL3-like therapeutic approaches — discuss with oncologist. Iron chelators (deferiprone, deferoxamine): Both chelate iron; spirulina phycocyanin is a weaker chelator; additive in mild iron overload; no clinically significant pharmacological conflict. N-acetylcysteine (NAC): NAC (cysteine precursor for GSH) and spirulina SLC7A11/cystine import both support GSH; mechanistically complementary; additive GSH elevation. Summary: GPx4 +25–35%, GSH +25–40%, 4-HNE/MDA −30–45%, ferroptosis cell death −40–60%; dosing 5–10g daily. NK concern: low (caution during ferroptosis-based cancer therapy).